Discover
INDP
Indaptus Therapeutics, Inc.
2.94
2 x 2.14
2 x 3.72
bid
ask
-
0.06
2.00%
2 @ 04:30 AM
2.93 -0.01 (0.34%)
| Ytd | 1.03% | |
| 1y | -73.63% |
2.88
day range
3.00
0.92
52 week range
13.40
| Open | 2.97 | Prev Close | 3.00 | Low | 2.88 | High | 3.00 | Mkt Cap | 391.73M |
| Vol | 50.76K | Avg Vol | 1.02M | EPS | -12.70 | P/E | N/A | Forward P/E | -0.64 |
| Beta | 1.13 | Short Ratio | 0.54 | Inst. Own | 6.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 2.59 | 200-d Avg | 2.53 | 1yr Est | 8.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.47 | -0.32 | 0.15 | 31.91% |
| 2024-08-12 | 2024-06 | -0.54 | -0.47 | 0.07 | 12.96% |
| 2024-05-08 | 2024-03 | -0.57 | -0.45 | 0.12 | 21.05% |
| 2024-03-13 | 2023-12 | -0.54 | -0.47 | 0.07 | 12.96% |
| 2023-11-06 | 2023-09 | -0.55 | -0.47 | 0.08 | 14.55% |
| 2023-08-14 | 2023-06 | -0.58 | -0.39 | 0.19 | 32.76% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-13 | Maxim Group | Upgrade | Buy | Buy |
| 2024-10-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-17 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-04-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-09-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-08-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-08-13 | ANDERSON GLEN R | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-11-24 | MECKLER JEFFREY A | Chief Executive Officer | 202.86K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Group Inc | 256.27K | 227.85K | 2.51% |
| 2024-09-29 | Investment House, LLC | 99.98K | 88.89K | 0.98% |
| 2024-09-29 | Geode Capital Management, LLC | 73.13K | 65.02K | 0.72% |
| 2024-09-29 | Strategy Asset Managers Llc | 45.34K | 40.31K | 0.44% |
| 2024-09-29 | Pine Valley Investments Ltd Liability Co. | 43.98K | 39.10K | 0.43% |
| 2024-09-29 | Renaissance Technologies, LLC | 27.10K | 24.09K | 0.27% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 229.20K | 203.78K | 2.25% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 44.17K | 39.27K | 0.43% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 27.07K | 24.07K | 0.27% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 14.12K | 12.56K | 0.14% |
| 2024-10-30 | Fidelity Total Market Index Fund | 12.95K | 11.51K | 0.13% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 9.31K | 8.28K | 0.09% |
Split
| Split | Date |
|---|---|
| 1 : 28 | 2025-06-27 |
| 1 : 4 | 2021-07-27 |
| 1 : 20 | 2020-10-30 |